MARKET

CMPS

CMPS

Compass Pathways Plc
NASDAQ
9.61
-0.72
-6.97%
After Hours: 9.90 +0.29 +3.02% 19:51 02/08 EST
OPEN
10.32
PREV CLOSE
10.33
HIGH
10.35
LOW
9.51
VOLUME
363.68K
TURNOVER
--
52 WEEK HIGH
21.50
52 WEEK LOW
6.54
MARKET CAP
409.16M
P/E (TTM)
-4.7020
1D
5D
1M
3M
1Y
5Y
'Hawaii Senate Committee Approves Bill To Create Therapeutic Psilocybin Working Group' -Marijuana Moment Report
Benzinga · 23h ago
Psychedelic Stock Gainers And Losers From February 7, 2023
Benzinga · 1d ago
Mind Medicine, GH Research Among Top Psychedelic Movers Of Today
Benzinga · 2d ago
'Change To Classification Of Psilocybin And MDMA To Enable Prescribing By Authorized Psychiatrists'; Australia Allows Prescription of MDMA and Psilocybin in Groundbreaking Regulatory Change - Australian Government Department Of Health And Aged Care
Benzinga · 6d ago
Psychedelic Stock Gainers And Losers From February 1, 2023
Benzinga · 02/01 21:30
'Psychedelics Bills Filed In Four More States As 2023 Reform Efforts Heat Up' -Marijuana Moment Report
Benzinga · 02/01 19:47
GH Research, Mind Medicine Among Top Psychedelic Movers Of Today
Benzinga · 01/31 21:30
Intelgenx Technologies, Cybin Among Top Psychedelic Movers Of Today
Benzinga · 01/30 21:30
More
About CMPS
COMPASS Pathways plc is a United Kingdom-based mental healthcare company. The Company is developing psilocybin therapy through late-stage clinical trials in Europe and North America for patients with treatment-resistant depression (TRD). The Company has developed COMP360, which is a psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin. The Company's COMP360 has completed a Phase IIb clinical trial of psilocybin therapy for TRD, in 22 sites across Europe and North America. Its randomized controlled Phase IIb study of psilocybin therapy in treatment-resistant depression is the psilocybin therapy clinical trial, with approximately 233 patients across 22 sites in 10 European and North American countries. This trial assessed the safety and efficacy of COMP360 psilocybin therapy in three doses: 1mg, 10mg, 25mg. The Company is also running a Phase II clinical trial of COMP360 psilocybin therapy for post-traumatic stress disorder (PTSD).

Webull offers kinds of COMPASS Pathways PLC stock information, including NASDAQ:CMPS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CMPS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CMPS stock methods without spending real money on the virtual paper trading platform.